Literature DB >> 25491437

Preclinical diagnosis of American visceral leishmaniasis during early onset of human Leishmania (L.) infantum chagasi-infection.

Luciana Vieira do Rêgo Lima, Patrícia Karla Santos Ramos, Marliane Batista Campos, Thiago Vasconcelos dos Santos, Claudia Maria de Castro Gomes, Márcia Dalastra Laurenti, Carlos Eduardo Pereira Corbett, Fernando Tobias Silveira.   

Abstract

American visceral leishmaniasis (AVL) is an infectious disease, often with long-duration evolution, caused by Leishmania (L.) infantum chagasi. However, although the disease is considered the major clinical manifestation of the link between L. (L.) i. chagasi and the human immune response, we have recently identified five clinical-immunological profiles of infection in the Brazilian Amazon: three asymptomatic (Asymptomatic Infection--AI, Sub-clinical Resistant Infection--SRI, and Indeterminate Initial Infection--III), and two symptomatic ones [Symptomatic Infection--SI (=AVL) and Sub-clinical Oligosymptomatic Infection--SOI]. We confirm here the preclinical diagnosis of AVL through the IgM-antibody response in a case of an early infection (profile III) that evolved to the full disease after 6 weeks.

Entities:  

Keywords:  American visceral leishmaniasis; Human indeterminate initial infection,; IgM-antibody response,; Leishmania (L.) infantum chagasi,; Preclinical diagnosis,

Mesh:

Substances:

Year:  2014        PMID: 25491437      PMCID: PMC4394671          DOI: 10.1179/2047773214Y.0000000166

Source DB:  PubMed          Journal:  Pathog Glob Health        ISSN: 2047-7724            Impact factor:   2.894


  9 in total

1.  A prospective study on the dynamics of the clinical and immunological evolution of human Leishmania (L.) infantum chagasi infection in the Brazilian Amazon region.

Authors:  Fernando T Silveira; Ralph Lainson; José Angelo Crescente; Adelson A A de Souza; Marliane B Campos; Claudia M C Gomes; Márcia D Laurenti; Carlos E P Corbett
Journal:  Trans R Soc Trop Med Hyg       Date:  2010-06-09       Impact factor: 2.184

2.  Subclinical form of the American visceral leishmaniasis.

Authors:  Mônica Elinor Alves Gama; Jackson Maurício Lopes Costa; Cláudia Maria Castro Gomes; Carlos Eduardo Pereira Corbett
Journal:  Mem Inst Oswaldo Cruz       Date:  2005-03-04       Impact factor: 2.743

3.  Further evidences on a new diagnostic approach for monitoring human Leishmania (L.) infantum chagasi infection in Amazonian Brazil.

Authors:  Fernando Tobias Silveira; Ralph Lainson; Adelson Alcimar Almeida De Souza; Marliane Batista Campos; Liliane Almeida Carneiro; Luciana Vieira Rego Lima; Patrícia Karla Santos Ramos; Cláudia Maria de Castro Gomes; Marcia Dalastra Laurenti; Carlos Eduardo Pereira Corbett
Journal:  Parasitol Res       Date:  2009-11-28       Impact factor: 2.289

4.  A cross-sectional study on the clinical and immunological spectrum of human Leishmania (L.) infantum chagasi infection in the Brazilian Amazon region.

Authors:  José Angelo B Crescente; Fernando T Silveira; Ralph Lainson; Claudia M C Gomes; Márcia D Laurenti; Carlos E P Corbett
Journal:  Trans R Soc Trop Med Hyg       Date:  2009-07-16       Impact factor: 2.184

Review 5.  Clinical spectrum of Leishmaniasis.

Authors:  R D Pearson; A Q Sousa
Journal:  Clin Infect Dis       Date:  1996-01       Impact factor: 9.079

6.  The significance of blood levels of IgM, IgA, IgG and IgG subclasses in Sudanese visceral leishmaniasis patients.

Authors:  A M Elassad; S A Younis; M Siddig; J Grayson; E Petersen; H W Ghalib
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

7.  Differential decline in Leishmania membrane antigen-specific immunoglobulin G (IgG), IgM, IgE, and IgG subclass antibodies in Indian kala-azar patients after chemotherapy.

Authors:  K Anam; F Afrin; D Banerjee; N Pramanik; S K Guha; R P Goswami; S K Saha; N Ali
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

8.  Genes at human chromosome 5q31.1 regulate delayed-type hypersensitivity responses associated with Leishmania chagasi infection.

Authors:  S M B Jeronimo; A K B Holst; S E Jamieson; R Francis; D R A Martins; F L Bezerra; N A Ettinger; E T Nascimento; G R Monteiro; H G Lacerda; E N Miller; H J Cordell; P Duggal; T H Beaty; J M Blackwell; M E Wilson
Journal:  Genes Immun       Date:  2007-08-23       Impact factor: 2.676

9.  Serum cytokines associated with severity and complications of kala-azar.

Authors:  Dorcas L Costa; Regina L Rocha; Rayssa M A Carvalho; Adelino S Lima-Neto; Michael O Harhay; Carlos Henrique N Costa; Manoel Barral-Neto; Aldina P Barral
Journal:  Pathog Glob Health       Date:  2013-03       Impact factor: 2.894

  9 in total
  3 in total

1.  Serum Cytokine Responses over the Entire Clinical-Immunological Spectrum of Human Leishmania (L.) infantum chagasi Infection.

Authors:  Patrícia Karla Ramos; Karina Inácio Carvalho; Daniela Santoro Rosa; Ana Paula Rodrigues; Luciana Vieira Lima; Marliane Batista Campos; Claudia Maria C Gomes; Márcia Dalastra Laurenti; Carlos Eduardo Corbett; Fernando Tobias Silveira
Journal:  Biomed Res Int       Date:  2016-03-08       Impact factor: 3.411

2.  New record of preclinical diagnosis of American visceral leishmaniasis in Amazonian Brazil encourages optimizing disease control.

Authors:  Luciana Lima; Thiago Vasconcelos-Dos-Santos; Marliane Campos; Patrícia Karla Ramos; Claudia Gomes; Marcia Laurenti; Vania da Matta; Carlos Corbett; Fernando Silveira
Journal:  Parasite Epidemiol Control       Date:  2020-05-08

3.  Prevalence of asymptomatic Leishmania infection and associated risk factors, after an outbreak in the south-western Madrid region, Spain, 2015.

Authors:  Ana Victoria Ibarra-Meneses; Eugenia Carrillo; Javier Nieto; Carmen Sánchez; Sheila Ortega; Alicia Estirado; Pello Latasa Zamalloa; Juan Carlos Sanz; Luis García-Comas; María Ordobás; Javier Moreno
Journal:  Euro Surveill       Date:  2019-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.